Amarin Corp Plc (AMRN)

[ziploc_1]

Nsleven...Thank you for the essential info for the 'BRAVE study' on Alzheimers disease
Sponsor is VA office of R and D and collaborator is University of Wisconsin medical school...

Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 150 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Impact of Icosapent Ethyl on Alzheimers Disease Biomarkers in Preclinical Adults
Actual Study Start Date : June 8, 2017
Estimated Primary Completion Date : January 31, 2023
Estimated Study Completion Date : January 31, 2023